Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale

Our plain-English summary of Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale, by C. Cao, T.D. Yan, D.L. Morris, et al (Tumori, 2012).

The study

• Authors: C. Cao, T.D. Yan, D.L. Morris, K. van der Speeten, S. Laurberg, O. Glehen, K. Link, P. Piso, A.A. Tentes, M. Deraco, S.G. Larsen, D. Kecmanovic, L.G. Bayón, J.T. Melero, S. González-Moreno, H. Mahteme, P. Gertsch, B. Moran, J. Esquivel, R. Alexander, E.A. Levine, P.H. Sugarbaker
• Journal: Tumori
• Published: 2012;98(1):166-71
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

In plain English

This article described the plan for a study and reported no results from the study itself. The authors set out the design of the Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT), a registry for patients with diffuse malignant peritoneal mesothelioma, a cancer of the lining of the abdomen. Twenty centers in 13 countries agreed to take part. From March 2011 to February 2013, the centers were to collect standard information on every patient with the disease referred to them, whether or not the patient had surgery. The main aim was to compare overall survival after three treatments. The first was surgery to remove visible tumor (cytoreductive surgery) plus heated chemotherapy given inside the abdomen (HIPEC) plus the best chemotherapy given through the bloodstream. The second was surgery plus bloodstream chemotherapy. The third was bloodstream chemotherapy alone. Each patient was to be followed for at least 6 months. A statistical method called propensity score matching was planned to make the groups more comparable. Because a randomized trial was considered unlikely, the authors stated that the study was designed to offer the highest level of evidence on the best treatment.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Study design and rationale (protocol) for a prospective multi-center observational registry; no results from the registry reported
• Who was studied: Planned: all patients with diffuse malignant peritoneal mesothelioma (DMPM) referred to 20 participating centers in 13 countries, whether or not surgery was performed; recruitment planned from March 2011 to February 2013, with a minimum of 6 months of follow-up
• Exposure: The study compares treatments, not asbestos exposure: cytoreductive surgery (CRS) plus HIPEC plus best systemic chemotherapy; CRS plus best systemic chemotherapy; and best systemic chemotherapy alone
• The authors' conclusion: Because a randomized controlled trial was considered unlikely ever to be performed, the authors stated that PROMPT is designed to offer the highest level of evidence for deciding the best treatment for DMPM

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma, Peritoneal mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry — K.I. Votanopoulos, P. Sugarbaker, et al. (2018)
• A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design — F. Passiglia, P. Bironzo, et al. (2021)
• Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial — N.L. de Boer, J.P. van Kooten, et al. (2019)
• Importance of gender in diffuse malignant peritoneal mesothelioma — C. Cao, T.D. Yan, et al. (2012)
• Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry — A. Arjona-Sanchez, O. Aziz, et al. (2021)
• What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures — G. Passot, D. Vaudoyer, et al. (2016)

Browse more research in Tumori, or return to medical research.